AU2014220668B2 - A compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphoma - Google Patents
A compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphoma Download PDFInfo
- Publication number
- AU2014220668B2 AU2014220668B2 AU2014220668A AU2014220668A AU2014220668B2 AU 2014220668 B2 AU2014220668 B2 AU 2014220668B2 AU 2014220668 A AU2014220668 A AU 2014220668A AU 2014220668 A AU2014220668 A AU 2014220668A AU 2014220668 B2 AU2014220668 B2 AU 2014220668B2
- Authority
- AU
- Australia
- Prior art keywords
- kir3dl2
- antibody
- cells
- polypeptide
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361766798P | 2013-02-20 | 2013-02-20 | |
| US61/766,798 | 2013-02-20 | ||
| US201361831809P | 2013-06-06 | 2013-06-06 | |
| US61/831,809 | 2013-06-06 | ||
| PCT/EP2014/053340 WO2014128221A1 (en) | 2013-02-20 | 2014-02-20 | A compound that specifically binds to kir3dl2 for use in the treatment of peripheral t cell lymphoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2014220668A1 AU2014220668A1 (en) | 2015-08-20 |
| AU2014220668B2 true AU2014220668B2 (en) | 2018-12-13 |
Family
ID=50156759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014220668A Active AU2014220668B2 (en) | 2013-02-20 | 2014-02-20 | A compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphoma |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US20160002345A1 (cg-RX-API-DMAC7.html) |
| EP (3) | EP2958941B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6360077B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN105026427B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014220668B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2899241C (cg-RX-API-DMAC7.html) |
| DK (3) | DK3896088T3 (cg-RX-API-DMAC7.html) |
| ES (2) | ES2730011T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014128221A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9738724B2 (en) | 2012-06-08 | 2017-08-22 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| EP3135690A1 (en) | 2012-06-26 | 2017-03-01 | Sutro Biopharma, Inc. | Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use |
| RU2682449C2 (ru) | 2012-09-19 | 2019-03-19 | Иннейт Фарма | Связывающие kir3dl2 агенты |
| DK3896088T3 (da) | 2013-02-20 | 2025-09-29 | Innate Pharma | Behandling af perifert t-cellelymfom |
| US20160130346A1 (en) * | 2013-05-29 | 2016-05-12 | Institut National De La Sante Et De La Recherche Medicale | Kir3dl2 is a biomarker and a therapeutic target useful for respectively preventing and treating a subset of cutaneous and non-cutaneous peripheral t-cell lymphomas |
| WO2015006555A2 (en) | 2013-07-10 | 2015-01-15 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| EP3116908B1 (en) | 2014-03-14 | 2019-06-26 | Innate Pharma | Humanized kir3dl2 antibodies |
| WO2016030488A1 (en) * | 2014-08-27 | 2016-03-03 | Innate Pharma | Treatment of celiac disease |
| US10487153B2 (en) | 2015-06-10 | 2019-11-26 | National Research Council Of Canada | Carbonic anhydrase IX-specific antibodies and uses thereof |
| EP3325967B1 (en) | 2015-07-24 | 2019-12-04 | Innate Pharma | Methods for detecting tissue infiltrating nk cells |
| AU2017212739B2 (en) | 2016-01-27 | 2024-03-21 | Sutro Biopharma, Inc. | Anti-CD74 antibody conjugates, compositions comprising anti-CD74 antibody conjugates and methods of using anti-CD74 antibody conjugates |
| MX390955B (es) * | 2016-06-02 | 2025-03-19 | Seagen Inc | Uso de un anticuerpo anti-pd-1 en combinación con un anticuerpo anti-cd30 para el tratamiento de linfoma. |
| WO2018073363A1 (en) * | 2016-10-21 | 2018-04-26 | Innate Pharma | Treatment with anti-kir3dl2 agents |
| EP3658588A1 (en) * | 2017-07-26 | 2020-06-03 | Sutro Biopharma, Inc. | Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma |
| CN108319816B (zh) * | 2018-02-27 | 2021-04-23 | 广州大学 | 一种基于基因通路识别小分子核糖核酸的方法 |
| BR112021014236A2 (pt) * | 2019-01-22 | 2021-09-28 | Innate Pharma | Anticorpo, composição farmacêutica, kit e método para predizer ou avaliar a eficácia |
| WO2022214432A1 (en) * | 2021-04-05 | 2022-10-13 | Innate Pharma | Immunohistochemistry methods and kir3dl2-specific reagents |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010081890A1 (en) * | 2009-01-19 | 2010-07-22 | Innate Pharma | Anti-kir3d antibodies |
| US8222376B2 (en) * | 2005-01-06 | 2012-07-17 | Novo Nordisk A/S | KIR-binding agents and methods of use thereof |
| WO2014044681A1 (en) * | 2012-09-19 | 2014-03-27 | Innate Pharma | Kir3dl2 binding agents |
| WO2014044686A1 (en) * | 2012-09-19 | 2014-03-27 | Innate Pharma | Kir3dl2 binding agents |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5776427A (en) | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
| US5599790A (en) * | 1992-06-11 | 1997-02-04 | The Scripps Research Institute | Fibrinogen γ chain polypeptide and compositions thereof |
| AU717020B2 (en) | 1996-05-03 | 2000-03-16 | Immunomedics Inc. | Targeted combination immunotherapy of cancer |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| WO2001022972A2 (en) | 1999-09-25 | 2001-04-05 | University Of Iowa Research Foundation | Immunostimulatory nucleic acids |
| AU1922902A (en) | 2000-12-18 | 2002-07-01 | Inst Nat Sante Rech Med | Novel means for the diagnosis and therapy of CTCL |
| KR100911951B1 (ko) * | 2001-08-23 | 2009-08-13 | 젠맵 에이/에스 | 인터루킨 15 (il-15)에 대하여 특이적인 인간 항체 |
| PL213948B1 (pl) | 2001-10-25 | 2013-05-31 | Genentech Inc | Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| KR20050000380A (ko) | 2002-04-09 | 2005-01-03 | 교와 핫꼬 고교 가부시끼가이샤 | 게놈이 개변된 세포 |
| PT1534335E (pt) | 2002-08-14 | 2012-02-28 | Macrogenics Inc | Anticorpos específicos de fcγriib e processos para a sua utilização |
| AR040996A1 (es) | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | Acidos nucleicos inmunoestimuladores |
| JP2004126818A (ja) | 2002-09-30 | 2004-04-22 | Toshiba Corp | 電子機器システム、電池ユニットおよび電池ユニットの動作制御方法 |
| US7411045B2 (en) * | 2002-11-19 | 2008-08-12 | A&G Pharmaceutical, Inc. | Autocrine growth factor receptor antibodies and methods |
| US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| HUE033129T2 (en) * | 2003-07-24 | 2017-11-28 | Innate Pharma Sa | Methods and compositions for increasing the efficacy of therapeutic antibodies using compounds that potentiate NK cells |
| WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| EP1747237A4 (en) | 2004-04-16 | 2008-05-21 | Macrogenics Inc | SPECIFIC GAMMA FC ANTIBODIES AND METHODS OF USING THE SAME |
| CA2565874C (en) | 2004-05-10 | 2017-10-03 | Macrogenics, Inc. | Humanized fc.gamma.riib-specific antibodies and methods of use thereof |
| CA2601417C (en) * | 2004-07-01 | 2018-10-30 | Novo Nordisk A/S | Human anti-kir antibodies |
| AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
| KR20080032065A (ko) | 2005-06-03 | 2008-04-14 | 제넨테크, 인크. | 푸코실화 수준이 조절된 항체의 생성 방법 |
| DK2573114T3 (en) | 2005-08-10 | 2016-07-04 | Macrogenics Inc | The identification and production of antibodies with variant Fc regions, and methods of using same |
| FR2894982A1 (fr) | 2005-12-16 | 2007-06-22 | Lab Francais Du Fractionnement | Procede de preparation d'anticorps selectifs des recepteurs fc activateurs |
| WO2007071829A2 (en) | 2005-12-22 | 2007-06-28 | Dermagene Oy | Methods and means related to diseases |
| MX2008009220A (es) | 2006-01-17 | 2008-10-10 | Biolex Therapeutics Inc | Composiciones y metodos para la humanizacion y optimizacion de n-glicanos en plantas. |
| JP2009529331A (ja) | 2006-03-10 | 2009-08-20 | マクロジェニクス,インコーポレーテッド | 変異型重鎖を有する抗体の同定および工学的改変ならびにその使用方法 |
| CA2660592C (en) | 2006-05-26 | 2016-07-12 | Macrogenics, Inc. | Humanized fc.gamma.riib-specific antibodies and methods of use thereof |
| EP2032159B1 (en) | 2006-06-26 | 2015-01-07 | MacroGenics, Inc. | Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof |
| EP1878747A1 (en) | 2006-07-11 | 2008-01-16 | greenovation Biotech GmbH | Glyco-engineered antibodies |
| CA2664343C (en) * | 2006-10-02 | 2016-04-26 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human il-4 receptor |
| EP1995309A1 (en) | 2007-05-21 | 2008-11-26 | Vivalis | Recombinant protein production in avian EBx® cells |
| CA2767755C (en) * | 2009-07-17 | 2021-10-12 | Rigshospitalet | Inhibitors of complement activation |
| DK2542256T3 (da) | 2010-03-04 | 2019-08-26 | Macrogenics Inc | Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf |
| JP2013533746A (ja) * | 2010-07-06 | 2013-08-29 | アベオ ファーマシューティカルズ, インコーポレイテッド | 抗ron抗体 |
| DK3896088T3 (da) | 2013-02-20 | 2025-09-29 | Innate Pharma | Behandling af perifert t-cellelymfom |
| US20160130346A1 (en) | 2013-05-29 | 2016-05-12 | Institut National De La Sante Et De La Recherche Medicale | Kir3dl2 is a biomarker and a therapeutic target useful for respectively preventing and treating a subset of cutaneous and non-cutaneous peripheral t-cell lymphomas |
| EP3116908B1 (en) | 2014-03-14 | 2019-06-26 | Innate Pharma | Humanized kir3dl2 antibodies |
| WO2018073363A1 (en) | 2016-10-21 | 2018-04-26 | Innate Pharma | Treatment with anti-kir3dl2 agents |
| BR112021014236A2 (pt) | 2019-01-22 | 2021-09-28 | Innate Pharma | Anticorpo, composição farmacêutica, kit e método para predizer ou avaliar a eficácia |
-
2014
- 2014-02-20 DK DK21166926.2T patent/DK3896088T3/da active
- 2014-02-20 AU AU2014220668A patent/AU2014220668B2/en active Active
- 2014-02-20 US US14/769,158 patent/US20160002345A1/en not_active Abandoned
- 2014-02-20 CN CN201480009772.XA patent/CN105026427B/zh active Active
- 2014-02-20 ES ES14706017T patent/ES2730011T3/es active Active
- 2014-02-20 CA CA2899241A patent/CA2899241C/en active Active
- 2014-02-20 EP EP14706017.2A patent/EP2958941B1/en active Active
- 2014-02-20 EP EP19163475.7A patent/EP3521312B1/en active Active
- 2014-02-20 DK DK19163475.7T patent/DK3521312T3/da active
- 2014-02-20 DK DK14706017.2T patent/DK2958941T3/da active
- 2014-02-20 WO PCT/EP2014/053340 patent/WO2014128221A1/en not_active Ceased
- 2014-02-20 ES ES19163475T patent/ES2878749T3/es active Active
- 2014-02-20 EP EP21166926.2A patent/EP3896088B1/en active Active
- 2014-02-20 JP JP2015557484A patent/JP6360077B2/ja active Active
-
2017
- 2017-06-15 US US15/623,572 patent/US10174112B2/en active Active
-
2019
- 2019-01-07 US US16/240,906 patent/US11078275B2/en active Active
-
2021
- 2021-07-29 US US17/388,052 patent/US12084498B2/en active Active
-
2024
- 2024-09-04 US US18/823,932 patent/US20250092130A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8222376B2 (en) * | 2005-01-06 | 2012-07-17 | Novo Nordisk A/S | KIR-binding agents and methods of use thereof |
| WO2010081890A1 (en) * | 2009-01-19 | 2010-07-22 | Innate Pharma | Anti-kir3d antibodies |
| WO2014044681A1 (en) * | 2012-09-19 | 2014-03-27 | Innate Pharma | Kir3dl2 binding agents |
| WO2014044686A1 (en) * | 2012-09-19 | 2014-03-27 | Innate Pharma | Kir3dl2 binding agents |
Non-Patent Citations (2)
| Title |
|---|
| BOUAZIZ J. et al., "Circulating natural killer lymphocytes are potential cytotoxic effectors against autologous malignant cells in Sezary syndrome patients.", JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2005, vol. 125, no. 6, pages 1273 - 1278 * |
| ORTONNE N. et al., "Significance of circulating T-cell clones in Sézary syndrome.", BLOOD, 2006, vol. 107, no. 10, pages 4030 - 4038 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20190127463A1 (en) | 2019-05-02 |
| EP3521312B1 (en) | 2021-04-07 |
| US20250092130A1 (en) | 2025-03-20 |
| CN105026427B (zh) | 2019-12-24 |
| US10174112B2 (en) | 2019-01-08 |
| ES2730011T3 (es) | 2019-11-07 |
| EP2958941A1 (en) | 2015-12-30 |
| DK3896088T3 (da) | 2025-09-29 |
| EP3896088B1 (en) | 2025-07-23 |
| US11078275B2 (en) | 2021-08-03 |
| JP2016513104A (ja) | 2016-05-12 |
| DK2958941T3 (da) | 2019-06-24 |
| DK3521312T3 (da) | 2021-06-28 |
| EP3521312A1 (en) | 2019-08-07 |
| EP2958941B1 (en) | 2019-04-10 |
| CA2899241C (en) | 2023-03-28 |
| US20170298132A1 (en) | 2017-10-19 |
| WO2014128221A1 (en) | 2014-08-28 |
| EP3896088A1 (en) | 2021-10-20 |
| JP6360077B2 (ja) | 2018-07-18 |
| ES2878749T3 (es) | 2021-11-19 |
| US12084498B2 (en) | 2024-09-10 |
| CA2899241A1 (en) | 2014-08-28 |
| AU2014220668A1 (en) | 2015-08-20 |
| US20160002345A1 (en) | 2016-01-07 |
| CN105026427A (zh) | 2015-11-04 |
| US20210363248A1 (en) | 2021-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12084498B2 (en) | Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphoma | |
| US20240425586A1 (en) | Treatment of peripheral t cell lymphoma | |
| US20240124579A1 (en) | Kir3dl2 binding agents | |
| US20240391999A1 (en) | Treatment with anti-kir3dl2 agents | |
| JP7611834B2 (ja) | T細胞リンパ腫の処置 | |
| WO2016030488A1 (en) | Treatment of celiac disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |